 NEW YORK--BUSINESS WIRE--- RCKT GeneTherapy--Rocket Pharmaceuticals, Inc. NASDAQ: RCKT Rocket, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces presentations at the upcoming 62nd American Society of Hematology ASH Annual Meeting being held virtually December 5-8, 2020. There will be two oral presentations highlighting clinical data from the Fanconi Anemia FA and Leukocyte Adhesion Deficiency-I LAD-I programs a 